![]() ![]() There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? What's Next for Matinas Biopharma Holdings, Inc. Shares have lost about 53.3% since the beginning of the year versus the S&P 500's decline of -8%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. This compares to zero revenues a year ago.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |